Moreover, monoclonal antibodies directed against IL23p40 have shown beneficial effects in psoriasis patients and thus it is predicted that inhibition of IL-23 will abort Th17 cell differentiation and result in abrogation of psoriasis. This evidence concerns the gene IL23A and psoriasis.